Key result
PDGF-AB reduces myofibroblast differentiation and accelerates post-MI scar maturation across preclinical models.
Why the study?
Platelet-derived growth factors (PDGFs) are reported to induce fibroblast proliferation, myofibroblast differentiation, and fibrosis, yet previous work showed that PDGFs improve heart function post-MI without increasing fibrosis.
Does PDGF-AB infusion reduce myofibroblast differentiation and improve scar maturation in post-myocardial infarction models?
Does PDGF-AB infusion reduce myofibroblast differentiation and improve scar maturation in post-myocardial infarction models?
Answers are grounded in this paper and cite their sources.
PDGF-AB may serve as a therapeutic agent to manipulate post-MI scar maturation and improve cardiac function by reducing myofibroblast differentiation without increasing proliferation.
After myocardial infarction (MI), fibroblasts progress from proliferative to myofibroblast states, resulting in fibrosis. Platelet-derived growth factors (PDGFs) are reported to induce fibroblast proliferation, myofibroblast differentiation, and fibrosis. However, we have previously shown that PDGFs improve heart function post-MI without increasing fibrosis. We treated human cardiac fibroblasts with PDGF isoforms then performed RNA sequencing to show that PDGFs reduced cardiac fibroblasts myofibroblast differentiation and downregulated cell cycle pathways. Using mouse/pig MI models, we reveal that PDGF-AB infusion increases cell-cell interactions, reduces myofibroblast differentiation, does not affect proliferation, and accelerates scar formation. RNA sequencing of pig hearts after MI showed that PDGF-AB reduces inflammatory cytokines and alters both transcript variants and long noncoding RNA expression in cell cycle pathways. We propose that PDGF-AB could be used therapeutically to manipulate post-MI scar maturation with subsequent beneficial effects on cardiac function.
No takes yet. Share an insight, caveat, or question.
Hume et al. (2023) studied Myocardial infarction (n=6). Platelet-derived growth factor-AB (PDGF-AB) vs. Untreated or vehicle control (and TGF-β1 in vitro) was evaluated on Myofibroblast differentiation (α-SMA+ and α-SMA+ vimentin+ cells in the infarct zone) (p=<0.05). PDGF-AB reduced cardiac fibroblast-to-myofibroblast differentiation and accelerated post-MI scar maturation without increasing proliferation in human, mouse, and pig models.
Synapse has enriched 10 related papers. Consider them for comparative context: